Effect of Lactobacillus brevis SBC8803 on Gamma-Glutamyl Transferase in Japanese Habitual Drinkers: A Double-Blind, Placebo-Controlled Study

DOI: 10.4236/fns.2012.35092   PDF   HTML     3,778 Downloads   6,242 Views   Citations

Abstract

A randomized, double-blind, placebo-controlled clinical trial in Japanese habitual drinkers was conducted to evaluate the efficacy of Lactobacillus brevis SBC8803 to alleviate adverse effect of alcohol. Subjects who drank habitually and had moderately higher levels of gamma-glutamyl transferase (GGT) (50 - 100 IU/L) were enrolled. The levels of transaminases in these subjects were almost within normal levels (aspartate transaminase (AST) <30 IU/L and alanine transaminase (ALT) <40 IU/L). Either the capsules containing placebo (n = 23) or 130 mg (4.0 × 1010 colony-forming units) of live L. brevis SBC8803 (n = 22) per day were administered for the continuous eight weeks (56 days). During the period, the subjects both in test group and placebo groups have kept each drinking behavior as usual. Regarding lipid metabolism, triacylglycerol (TG) levels in the male test group significantly decreased at week 4 as compared with week 0. Biomarkers of hepatocytes-damage; AST and ALT levels showed no significant differences between the pla- cebo and test groups at both weeks 4 and 8. Oxidative stress marker; GGT at weeks 4 was significantly lower in the test group than that in the placebo group (p = 0.017), but not at weeks 8. However, taking a reduced rate of GGT at weeks 8 comparing with that at week 0, that in the test group showed larger value comparing with that in the placebo group. These data about TG and GGT suggest that, although efficacy of L. brevis SBC8803 is limited in this study, intake of the probiotic may alleviate alcoholic influence in lipid metabolism and oxidative stress.

Share and Cite:

Y. Wakita, H. Kanda, C. Shimizu, Y. Nakakita, H. Kaneda, S. Segawa, M. Ozaki, T. Shigyo, T. Ohtake, M. Fujiya and Y. Kohgo, "Effect of Lactobacillus brevis SBC8803 on Gamma-Glutamyl Transferase in Japanese Habitual Drinkers: A Double-Blind, Placebo-Controlled Study," Food and Nutrition Sciences, Vol. 3 No. 5, 2012, pp. 678-684. doi: 10.4236/fns.2012.35092.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] World Health Organization, “Global Status Report on Alcohol and Health,” 2011.
[2] Ministry of Health, Labour and Welfare, “The National Nutrition Survey in Japan (in Japanese),” 2008.
[3] Ministry of Welfare, “The Alcohol-Related Problems in Japan (in Japanese),” 1993.
[4] S. Stewart and C. Day, “Alcohol and the Liver,” In: J. S. Dooley, A. S. F. Lok, A. K. Burroughs and E. J. Heathcote, Eds., Sherlok’s Disease of The Liver and Biliary System, 12th Edition, Wiley-Blackwell, Oxford, 2011, pp. 507-520.
[5] T. Neumann and C. Spies, “Use of Biomarkers for Alcohol Use Disorders in Clinical Practice,” Addiction, Vol. 98, Suppl. 2, 2003, pp. 81-91. doi:10.1046/j.1359-6357.2003.00587.x
[6] V. Tahan, B. Canbakan, H. Balci, F. Dane, H. Akin, G. Can, I. Hatemi, V. Olgac, A. Sonsuz, G. Ozbay, I. Yurdakul and H. Senturk, “Serum Gamma-Glutamyltranspeptidase Distinguishes Non-Alcoholic Fatty Liver Disease at High Risk,” Hepato-Gastroenterology, Vol. 55, No. 85, 2008, pp. 1433-1438.
[7] C. Meisinger, H. L?wel, M. Heier, A. Schneider and B. Thorand, “KORA Study Group. Serum Gamma-Glutamyltranferase and Risk of Type 2 Diabetes Mellitus in Men and Women from the General Population,” Journal of Internal Medicine, Vol. 258, No. 6, 2005, pp. 527-535. doi:10.1111/j.1365-2796.2005.01572.x
[8] E. Ruttmann, L. J. Brant, H. Concin, G. Diem, K. Rapp and H. Ulmer, Vorarlberg Health Monitoring and Promotion Program Study Group, “Gamma-Glutamyltransferase as a Risk Factor for Cardiovascular Disease Mortality: An Epidemiological Investigation in a Cohort of 163,944 Austrian Adults,” Circulation, Vol. 112, No. 14, 2005, pp. 2130-2137. doi:10.1161/CIRCULATIONAHA.105.552547
[9] D. H. Lee, R. Blomhoff and D. R. Jacobs, “Is Serum Gamma Glutamyltransferase a Marker of Oxidative Stress?” Free Radical Research, Vol. 38, No. 6, 2004, pp. 535-539. doi:10.1080/10715760410001694026
[10] A. O. Rantala, M. Lilja, H. Kauma, M. J. Savolainen, A. Reunanen and Y. A. Kes?niemi, “Gamma-Glutamyl Transpeptidase and the Metabolic Syndrome,” Journal of Internal Medicine, Vol. 248, No. 3, 2000, pp. 230-238. doi:10.1046/j.1365-2796.2000.00723.x
[11] I. A. Kirpich, N. V. Solovieva, S. N. Leikhter, N. A. Shidakova, O. V. Lebedeva, P. I. Sidorov, T. A. Bazhukova, A. G. Soloviev, S. S. Barve, C. J. McClain and M. Cave, “Probiotics Restore Bowel Flora and Improve Liver Enzymes in Human Alcohol-Induced Liver Injury: A Pilot Study,” Alcohol, Vol. 42, No. 8, 2008, pp. 675-682. doi:10.1016/j.alcohol.2008.08.006
[12] F. Higashikawa, M. Noda, T. Awaya, K. Nomura, H. Oku and M. Sugiyama, “Improvement of Constipation and Liver Function by Plant-Derived Lactic Acid Bacteria: A Double-Blind, Randomized Trial,” Nutrition, Vol. 26, No. 4, 2010, pp. 367-374. doi:10.1016/j.nut.2009.05.008
[13] S. Segawa, Y. Wakita, H. Hirata, J. Watari, “Oral Administration of Heat-Killed Lactobacillus brevis SBC8803 Ameliorates Alcoholic Liver Disease in Ethanol-Containing Diet-Fed C57BL/6N Mice,” International Journal of Food Microbiology, Vol. 128, No. 2, 2008, pp. 371377. doi:10.1016/j.ijfoodmicro.2008.09.023
[14] C. S. Lieber, “Alcoholic Fatty Liver: Its Pathogenesis and Mechanism of Progression to Inflammation and Fibrosis,” Alcohol, Vol. 34, Vol. 1, 2004, pp. 9-19.
[15] T. M. Donohue, “Alcohol-Induced Steatosis in Liver Cells,” World Journal of Gastroenterology, Vol. 13, No. 37, 2007, pp. 4974-4978.
[16] M. You and D. W. Crabb, “Molecular Mechanism of Alcoholic Fatty Liver: Role of Sterol Reguratory Element-Binding Proteins,” Alcohol, Vol. 34, No. 1, 2004, pp. 39-43. doi:10.1016/j.alcohol.2004.07.004
[17] N. Ueno, M. Fujiya, S. Segawa, T. Nata, K. Moriichi, H. Tanabe, Y. Mizukami, N. Kobayashi, K. Ito and Y. Kohgo, “Heat-Killed Body of Lactobacillus Brevis SBC8803 Ameliorates Intestinal Injury in a Murine Model of Colitis by Enhancing the Intestinal Barrier Function,” Inframmatory Bowel Disease, Vol. 17, No. 11, 2011, pp. 2235-2250.
[18] S. Segawa, M. Fujiya, H. Konishi, N. Ueno, N. Kobayashi, T. Shigyo T and Y. Kohgo, “Probiotic-Derived Polyphosphate Enhances the Epithelial Barrier Function and Maintains Intestinal Homeostasis through Integrinp38 MAPK Pathway,” PLoS One, Vol. 6, No. 8, 2011, Article ID: e22378. doi:10.1371/journal.pone.0023278

  
comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.